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Frontotemporal dementia is a heterogeneous neurodegenerative disorder characterized by neuronal loss in the frontal and temporal
lobes. Despite progress in understanding which genes are associated with the aetiology of frontotemporal dementia, the biological
basis of how mutations in these genes lead to cell loss in specific cortical regions remains unclear. In this work, we combined gene
expression data for 16 772 genes from the Allen Institute for Brain Science atlas with brain maps of grey matter atrophy in symp-
tomatic C9orf72, GRN and MAPT mutation carriers obtained from the Genetic Frontotemporal dementia Initiative study. No sig-
nificant association was seen between C9orf72, GRN and MAPT expression and the atrophy patterns in the respective genetic
groups. After adjusting for spatial autocorrelation, between 1000 and 5000 genes showed a negative or positive association with
the atrophy pattern within each individual genetic group, with the most significantly associated genes being TREM2, SSBP3 and
GPR158 (negative association in C9Orf72, GRN and MAPT respectively) and RELN, MXRA8 and LPA (positive association in
C9Orf72, GRN and MAPT respectively). An overrepresentation analysis identified a negative association with genes involved in
mitochondrial function, and a positive association with genes involved in vascular and glial cell function in each of the genetic
groups. A set of 423 and 700 genes showed significant positive and negative association, respectively, with atrophy patterns in all
three maps. The gene set with increased expression in spared cortical regions was enriched for neuronal and microglial genes, while
the gene set with increased expression in atrophied regions was enriched for astrocyte and endothelial cell genes. Our analysis sug-
gests that these cell types may play a more active role in the onset of neurodegeneration in frontotemporal dementia than previous-
ly assumed, and in the case of the positively associated cell marker genes, potentially through emergence of neurotoxic astrocytes
and alteration in the blood–brain barrier, respectively.
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Frontotemporal dementia (FTD) is a heterogeneous neu-
rodegenerative disorder characterized by neuronal loss in
the frontal and temporal lobes, with clinical symptoms
including behavioural, language and motor deficits
(Seelaar et al., 2011). Around 30% of FTD is familial,
most commonly caused by autosomal dominant genetic
mutations in one of three genes: progranulin (GRN),
microtubule-associated protein tau (MAPT) or chromo-
some 9 open reading frame 72 (C9orf72) (Rohrer et al.,
2009). Despite progress in understanding the patho-
physiological basis of genetic FTD, the biological basis of
how mutations in these genes leads to cell loss in specific
cortical regions and subsequently to specific clinical phe-
notypes is unclear.
An alternative approach to elucidating the molecular
biology of autosomal dominant FTD is to study the gene
expression profiles of brain regions which are atrophic in
symptomatic mutation carriers. This approach has been
enabled by publicly available data from the Allen
Institute for Brain Science which features post-mortem
high-resolution brain-wide gene expression data (i.e. the
Allen Atlas) from cognitively normal individuals
(Hawrylycz et al., 2012, 2015). In recent years, the Allen
Atlas has been successfully integrated with brain maps
obtained from case–control studies. For instance, in the
case of neurodegenerative disorders, one study investi-
gated the link between gene expression and both regional
patterns of atrophy and amyloid deposition, finding a
positive correlation of APP gene expression and amyloid
(Grothe et al., 2018), whilst another study showed that
expression of the MAPT gene was associated with
changes in functional connectivity in Parkinson’s disease
(Rittman et al., 2016).
In this work, we combine gene expression data from
the Allen Atlas with brain maps of grey matter atrophy
in symptomatic C9orf72, GRN and MAPT mutation car-
riers from the genetic FTD initiative (GENFI) study com-
pared with non-carriers (Cash et al., 2018). The aim of
this study was to investigate the molecular basis of the
atrophy pattern in mutation carriers. We firstly investi-
gated the spatial overlap between grey matter atrophy in
each of the three genetic groups and the gene expression
of the corresponding gene. We then aimed to identify
which genes showed a high spatial correspondence be-
tween their expression throughout the brain and the atro-
phy pattern in each genetic group. We hypothesized that
these genes or groups of genes may implicate molecular
processes or brain cell types that explain why these
regions are particularly vulnerable in FTD.
Materials and methods
Allen Human Brain Atlas data
We used the brain-wide microarray gene expression data
generated by the Allen Institute for Brain Science (down-
loaded from http://human.brain-map.org/) (Hawrylycz
et al., 2012, 2015). The dataset consists of a total of
3702 microarray samples from six donors (one female).
Each sample comprised 58 692 gene probes and provides
coordinates in MNI152 space. The gene expression data
Graphical Abstract








s/article/2/2/fcaa122/5894479 by guest on 20 N
ovem
ber 2020
have been normalized and corrected for batch effects by
the Allen Institute (TECHNICAL WHITE PAPER:
MICROARRAY DATA NORMALIZATION, 2013). We
first restricted the set of samples to the left hemisphere
(six in total) and to cortical regions based on the pro-
vided slab type (‘cortex’), retaining only samples with a
maximal distance of 3 mm to a cortical region of interest
obtained by a parcellation (Cardoso et al., 2015) of the
study template used in Cash et al. (2018). After addition-
ally removing samples being annotated by the Allen
Institute as non-cortical samples (e.g. CA1 field), 1248
microarray samples were available in total. Next, as pre-
viously described (Richiardi et al., 2015) we reannotated
all microarray probe sequences with gene names using
Re-Annotator (Arloth et al., 2015). We excluded probes
that sampled more than one gene (N¼ 1512), were
mapped to intergenic regions (N¼ 5013) or could not be
mapped to any genomic region (N¼ 1569), leaving
50 598 probes covering 19 980 unique genes.
Furthermore, we removed probes that were marked as
expressed in <300 of the 1248 cortical samples
(N¼ 13 941). Thus, the analysis was carried out using
36 657 microarray probes covering 16 772 distinct
genes.
Image data preparation
To quantify the amount of atrophy in carriers of FTD
mutations, we used results from a voxel-based morphom-
etry (VBM) analysis of the GENFI dataset (Cash et al.,
2018). In particular, in this analysis we used the maps
showing the voxel-wise t-statistic (t-maps) comparing
symptomatic mutation carriers (MAPT: N¼ 10; GRN:
N¼ 12; C9orf72: N¼ 25) to non-carriers (N¼ 144)
(Fig. 1; top). Here, higher t-scores signify higher average
atrophy in the symptomatic group analysis. A mean bias
corrected image from all the normalized T1 images in the
GENFI study served as a study template. This template
was warped into Montreal Neurological Institute and
Hospital space using the non-rigid registration based on
fast free form deformation implemented in NiftyReg (ver-
sion 10.4.15) (Modat et al., 2010). The obtained trans-
formation was then applied to each of the three t-maps.
For each Montreal Neurological Institute and Hospital
coordinate of the eligible cortical gene expression samples
we located the corresponding voxel in the t-map and
obtained the t-value centred on those Montreal
Neurological Institute and Hospital coordinates. This pro-
cedure was carried out for each of the three t-maps and
resulted in a 1248 by three matrix, i.e. each gene expres-
sion sample was linked to three t-scores from the VBM
analysis (one for each FTD gene).
Association analysis
The overall analysis is depicted in Fig. 1. We analysed
the association between atrophy and gene expression in a
quasi-non-parametric fashion. For a given atrophy map
and a given probe, we approximated the Spearman (or
rank) correlation (q) between the local t-score and the
gene expression level separately for each of the six
donors while accounting for spatial autocorrelation. This
was achieved by first converting t-scores and expression
levels into ranks, respectively, and using linear regression
to approximate the Spearman rank correlation (Conover
and Iman, 1981); and second by adjusting this linear
model using spatial eigenvectors that account for the spa-
tial relationship between samples. More precisely, we
used the method of spatial eigenvector mapping [reviewed
in Dormann et al. (2007)] to adjust for spatial autocor-
relation. In this approach, one first checks the residuals
of the linear model for presence of spatial autocorrelation
using Moran’s I (Moran, 1950), which assumes spatial
stationarity of the autocorrelation across the brain. If
there was evidence for spatial autocorrelation (as indi-
cated by P< 0.05 obtained with the moran.test function
in the spdep R package), then the first spatial eigenvector
was added as a confound variable to the linear model.
Next, if the residuals of the resulting extended linear
model continued to show evidence for spatial autocorrel-
ation, then further eigenvectors were added until the re-
sidual was free from evidence of spatial autocorrelation
(i.e. P> 0.05). To accelerate the process, spatial eigenvec-
tors were added to the model in batches of 5 and up to
150 spatial eigenvectors were considered. Spatial eigen-
vectors for this analysis were obtained from the 10-near-
est neighbour graph constructed using the geodesic
distances between gene expression samples, which were
generated for each donor brain. From the resulting linear
model, we extracted the t-scores and the corresponding
P-value for the association between atrophy and gene ex-
pression. Next, we combined the six P-values into a sin-
gle meta P-value using the weighted sum of Z-scores
(Stouffer’s) method. On purpose, we restricted weights to
1 and þ1 to only indicate the direction of association,
and to avoid over-emphasizing the impact of donors with
more gene expression samples. This procedure was car-
ried out for each for the 36 657 probes and each of the
three genetic group atrophy maps. P-values in each of the
three resulting lists were corrected for multiple testing
using the method by Benjamini and Hochberg (1995) for
false discovery rate (FDR).
Significantly positively correlated genes (i.e. higher gene
expression is linked to higher atrophy) were those where
any probe targeting the gene reached an FDR-corrected
P-value < 0.05 and a positive Z-score; likewise signifi-
cantly negatively correlated genes (i.e. higher gene expres-
sion is linked to lower atrophy) were required to have an
FDR-corrected P-value < 0.05 and a negative Z-score for
any of the probes targeting that gene. We also created
two overlap lists, one containing the overlap of genes in
the three positive lists, the other the overlap of genes in
all three negative lists. In the following we refer to these
two lists as consensus lists.
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Figure 1 Analysis overview. Starting point of the analysis are the statistical maps from VBM analyses comparing healthy controls and
symptomatic FTD mutation carriers in C9orf72, GRN and MAPT from Cash et al. (2018). For each statistical map the spatial association with the
expression levels 16 772 genes (represented by 36 657 gene expression probes) is computed using data from the Allen Institute for Brain Science
gene expression atlas. The resulting gene ranking provides lists of genes that are either significantly (PFDR<0.05) positively or negatively
correlated with the atrophy pattern. Two consensus lists were generated from the three lists of positively correlated and negatively correlated
genes, respectively. Resulting gene lists were analysed for enrichment of signature genes for brain cell types, such as neurons, microglia or
astrocytes and biological pathways.












To identify cellular pathways or cellular processes and
cell-type signature genes that may be enriched in the sig-
nificant gene lists, we conducted an overrepresentation
analysis. We obtained the following gene sets from the
MSigDB database version 6.1 (date accessed 23
November 2017): (i) Gene Ontology (GO) (N¼ 5917
sets), (ii) REACTOME (N¼ 674 pathways) and (iii)
KEGG (N¼ 186 pathways). We used Fisher’s exact test
to compute the odds ratio (OR) and P-value for overre-
presentation of genes in a given set. All tests were carried
out using the 16 772 cortex expressed genes as the back-
ground set. For each of the three gene lists (i.e. one per
FTD gene) and the two consensus lists we corrected the
P-values using the FDR correction based on Benjamini
and Hochberg across all 6777 gene sets.
To determine whether the expressed genes implicate a
specific class of brain cell types, in addition to enrich-
ment analysis for GO terms and pathways, we conducted
an enrichment analysis for marker gene lists for six brain
cell-types based on RNA sequencing of purified human
cells (Zhang et al., 2016). In brief, we generated cell-type
specific lists from the available average expression levels
per cell-type: only genes with expression levels exceeding
2.5 fragments per kilobase were included and genes were
required to show an enrichment of at least 3.0 (i.e. frag-
ments per kilobase in target cell-type divided by average
fragments per kilobase in non-target cell-types).
Expression-weighted cell-type
enrichment analysis
In an additional analysis we sought to identify poten-
tial brain cell types that were implicated by all three
FTD genes. To this end we conducted expression-
weighted cell-type enrichment (EWCE) analysis (Skene
and Grant, 2016) on the two consensus lists using a
recently published dataset of brain single-cell sequenc-
ing data in the mouse brain that identified 265 differ-
ent cell types (www.mousebrain.org) (Zeisel et al.,
2018). From this dataset we removed 76 cell types
that were not directly brain related (e.g. cell belonging
to enteric nervous system or the spinal cord), leaving
189 different cell-type signatures. Each of the cell
types is also attributed with a high-level annotation
(astrocytes, ependymal, immune, neurons, oligos, vas-
cular). In brief, from the single cell mouse dataset we
used only genes that had a unique human homolog (1-
to-1 mapping). Then, we analysed the two consensus
lists separately for high-level cell-type enrichment using
EWCE with correction for gene length and GC con-
tent. EWCE was executed twice, once using high-level
annotations and once using the 189 cell-type annota-
tions. P-values are based on 100 000 permutations
and enrichment P-values were corrected for multiple
testing using the Benjamini and Hochberg method for




Overall, the type of gene expression profiling used in
Allen Atlas is based on measuring bulk expression of tis-
sue samples, i.e. a group of diverse cell types is sampled
at once and the resulting expression profile represents the
group average of this set of cells and their states. Thus,
in these analyses, genes positively correlated with atrophy
indicate potential cellular processes and cell types that
promote atrophy in genetic FTD. Conversely, genes that
are negatively correlated with atrophy indicate potential
cellular processes and cell types that confer resilience to
disease-related neurodegeneration.
Data availability
Statistical maps of the VBM analysis were obtained from
Cash et al. (2018) and are available upon request from
the lead author of that study. Cortical gene expression
data were obtained from the Allen Institute of Brain
Sciences and can be obtained at http://human.brain-map.
org/. Code for pre-processing expression data and con-
ducting the regional association analysis with adjustment
for spatial autocorrection can be accessed through:
https://github.com/andrealtmann/AIBS_FTD.
Results
We tested 16 776 genes (from 36 657 microarray probes)
for their association with atrophy pattern across the cor-
tex in genetic FTD (Fig. 1). The numbers of significant
probes (PFDR<0.05) and genes with their direction for
each of the three FTD genes are listed in Table 1. The
association results per probe are available as
Supplementary material (Dataset 1). The number of
included spatial eigenvectors to adjust for spatial autocor-
relation ranged from one to 25, with a median (inter
quartile range) of 5 (1–10).
C9orf72
The strongest association between C9orf72 expression and
the atrophy pattern in symptomatic chromosome 9 open
reading frame 72 repeat extension carriers was measured
with microarray probe CUST_7641_PI416261804, which
showed a non-significant negative association z ¼ 0.27
(PFDR¼0.23; Fig. 2).
The most negatively associated gene was TREM2 (triggering
receptor expressed on myeloid cells 2; represented by probe
A_23_P167941; z ¼ 6.26; PFDR¼6.94e07; Fig. 2; Table 2;
Supplementary Dataset 1). Top-ranked gene sets based on the
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significantly negatively correlated genes include genes related to
mitochondria (GO_MITOCHONDRIAL_PART; OR¼ 3.00;
PFDR¼1.77e35) and the respiratory chain (GO_RESPIRAT
ORY_CHAIN; OR¼ 9.92; PFDR¼5.91e19; Supplementary
Dataset 2). Notably, KEGG pathways for neurodegenerative
disorders were highly enriched (KEGG_PARKINSONS
_DISEASE OR¼ 7.35 PFDR¼8.74e20; KEGG_HUNTING
TONS_DISEASE OR¼ 4.99 PFDR¼8.18e18; KEGG_ALZ
HEIMERS_DISEASE OR¼ 4.15 PFDR¼4.38e14). Among
brain cell types, there was a strong enrichment for neuronal
genes (OR¼ 1.7; PFDR¼1.13e12) and microglia (OR¼ 1.59;
PFDR¼2.53e06; Supplementary Dataset 3).
The most significantly positively correlated gene was
reelin; represented by probe A_24_P309095; z¼ 7.94;
PFDR¼1.92e11; Fig. 2, Table 2. Top-ranked GO terms
for positively correlated genes included vascular develop-
ment and glial cell differentiation (GO_REGULATION
_OF_VASCULATURE_DEVELOPMENT OR¼ 2.28 PFDR
¼9.95e04; GO_GLIAL_CELL_DIFFERENTIATION OR
¼ 2.66 PFDR¼1.13e03; Supplementary Dataset 2). Among
brain cell types, there was a strong enrichment for genes
associated with oligodendrocytes (OR¼ 9.37; PFDR¼
3.1e54), endothelial cells (OR¼ 2.4; PFDR¼3.63e10)
and mature astrocytes (OR¼ 1.62; PFDR¼1.23e05;
Supplementary Dataset 3).
Progranulin
The strongest association between GRN expression and
the atrophy pattern in symptomatic GRN mutation car-
riers was measured with microarray probe
CUST_13046_PI416261804, which showed a non-signifi-
cant positive association z¼ 1.31 (PFDR¼0.13; Fig. 2).
The most significantly negatively correlated gene was
single-stranded DNA-binding protein 3; z ¼ 6.73;
PFDR¼1.57e07; Fig. 2; Table 2. For the negatively cor-
related genes, significantly enriched gene sets featured the
respiratory chain (e.g. REACTOME’s RESPIRATORY
_ELECTRON_TRANSPORT OR¼ 5.04 PFDR¼6.13e06;
Supplementary Dataset 2). As with chromosome 9 open
reading frame 72, the three KEGG pathways for neurode-
generative disorders were enriched (Alzheimer’s OR¼
2.38 PFDR¼3.64e03; Parkinson’s OR¼ 3.09 PFDR¼
2.17e04; Huntington’s OR¼ 2.26 PFDR¼5.32e03).
Among brain cell types, there was a strong enrichment
for neuronal genes (OR¼ 1.71; PFDR¼2.06e13) and
microglia (OR¼ 1.68; PFDR¼4.10e08; Supplementary
Dataset 3).
The most significantly positively associated gene was
matrix remodelling associated 8; z¼ 6.36;
PFDR¼5.87e07; Fig. 2; Table 2. Top-ranked GO terms
(Supplementary Dataset 2) for positively correlated genes
are related to the extracellular matrix (GO_EXTRAC
ELLULAR_MATRIX OR¼ 3.79 PFDR¼1.25e18), vascu-
lar development, (GO_VASCULATURE_DEVELOPME
NT OR¼ 2.68 PFDR¼4.16e11) and response to wound-
ing (GO_RESPONSE_TO_WOUNDING OR¼ 2.45 PFDR
¼9.19e10). Again, genes related to oligodendrocytes
showed the strongest enrichment (OR¼ 9.47; PFDR¼
6.1e53), followed by mature astrocytes (OR¼ 3.19;
PFDR¼6.62e32) and endothelial cells (OR¼ 4.21;
PFDR¼1.18e28; Supplementary Dataset 3).
Microtubule-associated protein tau
The strongest association between MAPT expression and
the atrophy pattern in symptomatic MAPT mutation
carriers was measured with microarray probe A_24_P
224488, which showed a non-significant positive associ-
ation z¼ 0.867 (PFDR¼0.15; Fig. 2).
The most significantly negatively correlated gene was G-
protein-coupled receptor 158; z ¼ 9.32; PFDR¼1.06e16;
Fig. 2; Table 2. As in the case of C9orf72, the significantly
negatively correlated genes showed enrichment for mitochon-
dria (GO_MITOCHONDRIAL_PART; OR¼ 2.11;
PFDR¼2.90e22) and cellular respiration
(GO_CELLULAR_RESPIRATION; OR¼ 3.69;
PFDR¼1.72e11; Supplementary Dataset 2). Notably, KEGG
pathways for neurodegenerative disorders were enriched
(Parkinson’s OR¼ 6.05 PFDR¼2.75e16; Alzheimer’s
OR¼ 3.37 PFDR¼7.76e11; Huntington’s OR¼ 3.08
PFDR¼4.47e10). Within the cell types, neuronal genes were
strongly enriched (OR¼ 2.26; PFDR¼2.22e46).
The most significantly positively associated gene was
lipoprotein(a); z¼ 8.32; PFDR¼6.48e11; Fig. 2; Table 2.
Significantly positively correlated genes are enriched for
genes related to nervous system development
(GO_REGULATION_OF_NERVOUS_SYSTEM_DEVELO
PMENT; OR¼ 1.83; PFDR¼3.03e08) and gliogenesis
(GO_GLIOGENESIS; OR¼ 2.66; PFDR¼2.57e06).
Furthermore, the positively correlated genes were strongly
enriched for genes related to mature astrocytes
(OR¼ 5.33, PFDR¼5.66e102) and moderately enriched
for oligodendrocytes related genes (OR¼ 1.78, PFDR¼
2.46e04; Supplementary Dataset 3).
Enrichment analyses for GO terms for each genetic
group and the consensus list are summarized in Fig. 3.
Consensus lists
From the gene lists obtained for each of the FTD gene at-
rophy maps we created two consensus lists: one
Table 1 Numbers of significant probes and genes and
their direction of association after Benjamini and
Hochberg correction for FDR
Probes Genes
Positive Negative Positive Negative
C9orf72 2208 2698 1830 2219
GRN 2078 2849 1635 2332
MAPT 4527 7530 3206 4972
Overlap 539 784 423 700
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comprising 423 genes that were significantly positively
correlated with atrophy in all three FTD genes and one
list comprising the 700 genes that were significantly nega-
tively correlated in all three maps (Fig. 1). Using these
lists, we aimed to identify a common theme underlying
the atrophy in the three causative genes.
The high-level analysis EWCE showed enrichment for vascu-
lar marker genes (Fig. 4; Z-score¼ 9.44; PFDR¼5.99e05),
astrocyte genes (Fig. 4; Z-score¼ 3.24; PFDR¼0.0033) among
genes with positive association to atrophy severity. Genes nega-
tively correlated with atrophy were highly enriched for neuron-
al genes (Z-score¼ 6.65; PFDR<5.99e05) and immune cell
Figure 2 Selected scatterplots between t-scores and gene expression levels. Rows correspond to the three different FTD genes
(C9orf72, GRN and MAPT). x-Axis shows to the t-value in the corresponding statistical VBM maps (Fig. 1) from Cash et al. (2018) at positions
where microarray samples were obtained in the Allen Atlas; the y-axis represents the expression levels in the Allen Atlas after adjustment for
spatial autocorrelation for the gene named at the top of the scatter plot. Each point represents one microarray sample and the colour indicates
the donor ID. In the first column expression of the corresponding FTD genes is studied: C9orf72 (CUST_7641_PI416261804), GRN
(CUST_13046_PI416261804) and MAPT (A_24_P224488). The second column shows the most strongly negatively correlated genes, i.e. genes
with high expression in brain regions showing little atrophy: TREM2 (A_23_P167941), SSBP3 (A_23_P500333) and GPR158 (A_24_P349117). The
third column shows the genes where expression level and atrophy positively correlate the strongest: RELN (A_24_P309095), MXRA8
(A_23_P32444) and LPA (A_23_P95221).
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genes (Z-score¼ 2.56; PFDR¼0.019). The detailed EWCE ana-
lysis of the 189 cell-types confirmed the high-level analysis:
nearly all cell-types belonging to the astrocyte and vascular
classes showed significant enrichment in the positive consensus
list (Supplementary Dataset 4). The negative consensus list was
enriched for microglia and for inhibitory as well as excitatory
neurons.
These results were further confirmed using cell-type mark-
er genes derived from RNA sequencing of purified human
cells (Zhang et al., 2016) (Fig. 4; right column), with the
strongest enrichment being seen for astrocyte marker genes
(OR¼ 3.89; PFDR¼3.7e16). In addition, oligodendrocytes
marker genes were enriched among genes with positive as-
sociation to atrophy severity (OR¼ 2.61; PFDR¼2.04e04).
Table 2 Top 10 most positively and negatively correlated genes with atrophy patterns in genetic FTD
Rank C9orf72 GRN MAPT
Negative Positive Negative Positive Negative Positive
1 TREM2 RELN SSBP3 MXRA8 GPR158 LPA
2 RAB11FIP5 SCAPER KIF5A DCHS2 ITGBL1 NUPR1
3 FPR1 MXRA8 HLA-DPA1 NDNF STRBP STOM
4 EPDR1 MFAP4 PGM5P2 CRIP1 KCTD9 DCAF15
5 FXR1 FMOD WIBG FBLN2 ERRFI1 ARHGAP36
6 KATNAL2 CLIC5 MGC39584 CNR1 F7 ALCAM
7 FAM3B SRGAP1 CPLX2 TGFBI CD99L2 PON3
8 PLA2G7 NDNF POU6F2 RELN GLRX C1orf228
9 ABRACL DCLK3 C2 PODXL ST8SIA5 MXRA8
10 HIST1H4H ARHGAP36 NRG1 ARHGAP36 EMB DRAXIN
Rows correspond to the three genes and an overlap between all three lists.
Figure 3 Summary of GO enrichment analysis. Selected GO enrichment results for the three genetic groups and the consensus lists
(Cons.). The left panel shows enrichment for genes showing a significant positive association with atrophy while the right panel depicts
enrichments for negatively correlated genes. Significance of the enrichment is colour-coded: more saturated colours signify smaller P-values and
non-significant results (i.e. FDR corrected P-value > 0.05) appear white. Depicted GO terms were reduced by filtering based on the number of
genes (<500) and by clustering terms with similar meaning using the measure of semantic similarity introduced by Wang et al. (2007). The full list
of results is available in Supplementary Dataset 2. BP: biological process; MF: molecular function; CC: cellular component.
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The remaining gene set analyses confirmed results
obtained with the individual gene lists (Fig. 3;
Supplementary Dataset 2).
Discussion
We investigated the gene expression correlates of the cor-
tical regions specifically atrophic in the three main genetic
causes of FTD. Whilst there was no association with ex-
pression of the gene itself (i.e. C9orf72, GRN and
MAPT), our analysis revealed that groups of genes com-
monly associated with astrocytes and endothelial cells
showed higher expression levels in regions with more at-
rophy and genes commonly associated with neurons and
microglia showed higher expression levels in the relatively
spared regions.
Astrocytes are the most abundant cell-type in the
human CNS and carry out a plethora of functions includ-
ing biochemical support for the blood–brain barrier
(BBB)-forming endothelial cells, trophic support for neu-
rons, regulation of extracellular ion balance and partici-
pation in repair processes of the brain following injuries.
Astrocytes reacting to injuries in the central nervous sys-
tem, reactive astrocytes, are characterized by expression
of glial fibrillary acidic protein (GFAP). Depending on
the context, such reactive GFAP-positive astrocytes can
be neurotoxic (Liddelow and Barres, 2015; Liddelow
et al., 2017) or neuroprotective (Anderson et al., 2016).
There are already multiple lines of evidence linking astro-
cyte (dys-)function to neurodegeneration (Rodrı́guez
et al., 2009; Phatnani and Maniatis, 2015; Sofroniew,
2015) and to FTD in particular. For instance, histopatho-
logical studies in FTD have shown that severity of astro-
cytosis and astrocytic apoptosis correlates with the degree
of neuronal loss as well as with the stage of the disease
(Broe et al., 2004). In addition, astrocyte reactivity
appears to be region specific in that higher numbers of
reactive (GFAP-positive) astrocytes were found in the
frontal and temporal cortices of FTD patients compared
to controls (Martinac et al., 2001). These observations
extend to the CSF where levels of GFAP were increased
in various neurodegenerative disorders compared to cog-
nitively normal adults with the highest levels in FTD
patients (Ishiki et al., 2016). Martinac et al. (2001) found
that degrading astrocytes were inversely correlated with
cerebral blood flow in FTD. However, more importantly,
astrocytes derived from induced pluripotent stem cells of
patients with mutations in MAPT were found to demon-
strate increased vulnerability to oxidative stress and ex-
hibit disease-associated gene-expression changes
(Hallmann et al., 2017). Co-culture experiments of such
modified FTD astrocytes with previously healthy neurons
led, among other things, to increased oxidative stress in
these neurons. Hence, taken together, astrocyte reactivity
and activation of GFAP may well co-occur with disease
onset and progression in FTD.
A second cell-type for which we observed consistent en-
richment in brain regions with atrophy were endothelial
(or vascular) cells, whilst the overrepresentation analysis
was also enriched for vascular terms (circulatory system
development). Furthermore, matrix remodelling associated
8 was found in the top 10 for all three genetic group
lists—this gene codes for limitrin, a protein specific to the
glia limitans, a component of the BBB. Overall, this sug-
gests a role of the BBB in regional vulnerability in genetic
FTD. Dysfunction of the BBB has been implicated in the
aetiology of many neurodegenerative disorders (Sweeney
et al., 2018), with BBB permeability previously found to
be abnormal in patients with FTD (Janelidze et al.,
2017). The BBB is ubiquitous in the cortex, however, our
results based on bulk tissue gene expression profiling
would suggest regional differences in density of endothe-
lial cells and their link to disease specific atrophy pat-
terns. Indeed, vascular structure in the brain is known to
be heterogenous and characterized by differential patho-
physiological responses (Cavaglia et al., 2001).
Figure 4 Cell-type enrichment in consensus gene lists. Two
different methods were used to investigate cell-type signatures in
the two consensus lists (POS: gene expression is positively
correlated with atrophy; NEG: gene expression is negatively
correlated with atrophy). The left panels used the EWCE method
together with single-cell RNA sequencing data from mouse brains
(Zeisel et al., 2018); the enrichment is summarized as log10(PFDR).
The right panels used a classic over-representation analysis based
on Fisher’s exact test with cell-type signature genes obtained from
bulk RNA sequencing of purified human cells (Zhang et al., 2016).
The red dashed lines indicate statistical significance after FDR
correction [i.e. log10(0.05)]. Both approaches demonstrated a
strong neuronal and immune signature in negatively correlated
genes (upper panels) and a strong vascular and astrocyte signature
in positively correlated genes (lower panels). Cell types are
presented in alphabetical order from top to bottom.
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Brain regions that were relatively spared in FTD
showed higher expression of neuron-related genes. The
detailed EWCE analyses showed that both inhibitory and
excitatory neuron types were enriched (Supplementary
Dataset 4). Higher expression in spared regions implies
lower gene expression in affected regions, which by itself
could be a source for increased vulnerability since minor
perturbations in gene expression may have a dispropor-
tionate effect. However, given that gene expression data
was generated using bulk tissue sampling and that neu-
rons have a significant spatial spread via extended den-
dritic and axonal processes, the observed enrichment
signal could originate from differences between mRNA
located in the soma and in dendrites, respectively. A re-
cent pathway analysis of 2028 differentially dendritically
localized mRNA isoforms showed strong enrichment for
GO terms such as respiratory electron transport chain
(Middleton et al., 2019), similar to our enrichment pat-
tern. Indeed, a post hoc enrichment analysis of these den-
dritically localized mRNA isoforms [Supplementary Table
2 from Middleton et al. (2019)] confirmed strong enrich-
ment in all three individual gene lists (OR> 1.5,
P< 1.07e10) as well as the consensus list (OR¼ 1.92,
P¼ 5.35e09). Thus, this result may suggest increased
and decreased dendrite density in spared and affected
regions, respectively. Neuron morphology is very diverse
and notably neurons with selective vulnerability in FTD
such as von Economo neurons and fork cells (Kim et al.,
2012; Seeley et al., 2012) are morphologically character-
ized by large cell bodies and limited branching of
dendrites.
In addition to neuron-related genes, there was also an
enrichment of immune system-related genes (e.g. micro-
glia genes) in brain regions with reduced atrophy. Recent
works using 11C-PK-11195 PET, a marker of activated
microglia, have linked regional patterns of neuroinflam-
mation to protein aggregation in FTD (Bevan-Jones et al.,
2020; Malpetti et al., 2020). Furthermore, a number of
genes associated with immune function were strongly
negatively correlated with gene expression in the associ-
ation analysis. In particular, TREM2 showed the stron-
gest negative association in the C9orf72 list and was also
significantly associated in the GRN and MAPT lists (z <
4.39, PFDR<2.68e04); this is a transmembrane recep-
tor that participates in modulation of the immune re-
sponse. Heterozygous variants in TREM2 are known to
be a risk factor for Alzheimer’s disease (Guerreiro et al.,
2013) and levels of the TREM2 protein have been shown
to be abnormal in FTD (Heywood et al., 2018;
Woollacott et al., 2018).
Molecular pathways related to mitochondria were also
negatively correlated with gene expression in the analysis.
Mitochondrial abnormalities have recently been associ-
ated with FTD (Lau et al., 2018), particularly with
C9orf72 mutations (Lopez-Gonzalez et al., 2016; Choi
et al., 2019), although little is known at present about
the exact molecular mechanisms underlying such
dysfunction.
The three individual genetic group lists as well as the
consensus list feature significant enrichment for KEGG
pathways for Alzheimer’s, Parkinson’s and Huntington’s
disease. This may be due to a strong overlap in dendriti-
cally localized mRNA isoforms and these pathways.
Notably, the KEGG pathway for ALS, which features
only 53 genes, did not reach statistical significance after
FDR correction in any of the three groups (OR¼ 2.12,
P¼ 0.0198, PFDR¼0.59 in the GRN list, P> 0.05 in the
MAPT and C9orf72 lists).
Summarizing, we detected higher levels of astrocyte and
endothelial cell-related genes in regions with neurodegen-
eration in FTD and we found that genes associated with
neurons and microglia were more enriched in brain
regions that are spared in FTD. Furthermore, there was
enrichment for genes that are associated with mitochon-
dria, particularly cellular respiration, in regions that are
not affected by atrophy. These results confirm earlier
results from an unbiased proteomic screen of tissue sam-
ples where the modules related to synapse (M1), mito-
chondrion (M3) and neuron differentiation (M8) showed
negative associations with clinicopathological traits in
FTD, i.e. these three modules were consistently negatively
correlated with FTD pathology (Umoh et al., 2018).
Consistent with our results, there was a positive associ-
ation between clinicopathological traits and modules M5
(Extracellular matrix) and M6 (Response to biotic stimu-
lus), which both showed strong cell-type enrichment for
astrocyte-related proteins. Notably, gene sets associated
with the extracellular matrix were also enriched in our
analysis with regions showing increased atrophy in FTD
(Supplementary Dataset 2). While Umoh et al. (2018)
interpreted the negative (and positive) correlations in part
with a disease-related shift in cell population in the
sampled region of interests, our results extend this obser-
vation to regional cell-type densities since the gene ex-
pression samples were obtained from six cognitively
normal subjects.
In summary, our analysis of bulk tissue expression data
suggests that cortical regions exhibiting the most severe
atrophy in genetic FTD may be those with higher expres-
sion of astrocyte and endothelial cell-related genes in
healthy subjects. Regional cell-density measurements
obtained from post-mortem histological samples of
healthy subjects would be required to confirm this find-
ing. However, our observation fits well with increased
BBB permeability in FTD patients and recent findings of
the neurotoxic potential of astrocytes (Liddelow et al.,
2017). We hypothesize that the distinct regional atrophy
pattern in genetic FTD may be driven by regions with
naturally increased astrocyte density where these universal
astrocyte neurotoxic effects come to bear with higher fre-
quency. Thus, neurodegeneration may be the result of
age-related increase in neurotoxic (A1) and senescent
astrocytes, which lost many normal astrocytic functions.












A.A. holds a Medical Research Council eMedLab
Medical Bioinformatics Career Development Fellowship.
This work was supported by the Medical Research
Council (grant number MR/L016311/1). The Dementia
Research Centre is supported by Alzheimer’s Research
UK, Brain Research Trust and The Wolfson Foundation.
This work was supported by the National Institute for
Health Research Queen Square Dementia Biomedical
Research Unit, the National Institute for Health Research
UCL/H Biomedical Research Centre and the Leonard
Wolfson Experimental Neurology Centre (LWENC)
Clinical Research Facility as well as an Alzheimer’s
Society grant (AS-PG-16-007). J.D.R. is supported by a
Medical Research Council Clinician Scientist Fellowship
(MR/M008525/1) and has received funding from the
National Institute for Health Research Rare Disease
Translational Research Collaboration (BRC149/NS/MH).
This work was also supported by the Medical Research
Council UK GENFI grant (MR/M023664/1) and the
Bluefield Project. M.R. holds a Medical Research Council
Clinician Scientist Fellowship (grant number MR/
N008324/1). R.H.R. was supported through the award
of a Leonard Wolfson Doctoral Training Fellowship in
Neurodegeneration. This work was supported by Italian
Ministry of Health (CoEN015 and Ricerca Corrente).
Several authors of this publication (J.C.v.S., M.S., R.S-V.,
A.D., M.O., J.B.R.) are members of the European
Reference Network for Rare Neurological Diseases—
Project ID No. 739510. This project was supported, in
part, via the European Union’s Horizon 2020 research
and innovation programme grant 779257 “Solve-RD” (to
M.S.).
Supplementary material
Supplementary material is available at Brain
Communications online.
Competing interests
The authors report no competing interests.
References
Anderson MA, Burda JE, Ren Y, Ao Y, O’Shea TM, Kawaguchi R,
et al. Astrocyte scar formation aids central nervous system axon re-
generation. Nature 2016; 532: 195–200.
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GM, et al. Disruption of ER-mitochondria signalling in fronto-tem-
poral dementia and related amyotrophic lateral sclerosis. Cell Death
Dis 2018; 9: 327.
Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ,
Schirmer L, et al. Neurotoxic reactive astrocytes are induced by acti-
vated microglia. Nature 2017; 541: 481–7.








s/article/2/2/fcaa122/5894479 by guest on 20 N
ovem
ber 2020
Liddelow S, Barres B. SnapShot: astrocytes in health and disease. Cell
2015; 162: 1170.e1.
Lopez-Gonzalez R, Lu Y, Gendron TF, Karydas A, Tran H, Yang D,
et al. Poly(GR) in C9ORF72-related ALS/FTD compromises mito-
chondrial function and increases oxidative stress and DNA damage
in iPSC-derived motor neurons. Neuron 2016; 92: 383–91.
Malpetti M, Rittman T, Jones PS, Cope TE, Passamonti L, Jones
WRB, et al. In vivo PET imaging of neuroinflammation in familial
frontotemporal dementia. medRxiv 2020. doi:
10.1101/2020.05.11.20098046.
Martinac JA, Craft DK, Su JH, Kim RC, Cotman CW. Astrocytes de-
generate in frontotemporal dementia: Possible relation to hypoperfu-
sion. Neurobiol Aging 2001; 22: 195–207.
Middleton SA, Eberwine J, Kim J. Comprehensive catalog of dendriti-
cally localized mRNA isoforms from sub-cellular sequencing of sin-
gle mouse neurons. BMC Biol 2019; 17: 16.
Modat M, Ridgway GR, Taylor ZA, Lehmann M, Barnes J, Hawkes
DJ, et al. Fast free-form deformation using graphics processing units.
Comput Methods Programs Biomed 2010; 98: 278–84.
Moran PAP. Notes on continuous stochastic phenomena. Biometrika
1950; 37: 17–23.
Phatnani H, Maniatis T. Astrocytes in neurodegenerative disease. Cold
Spring Harb Perspect Biol 2015; 7: a020628.
Richiardi J, Altmann A, Milazzo A-C, Chang C, Chakravarty MM,
Banaschewski T, et al. Correlated gene expression supports syn-
chronous activity in brain networks. Science 2015; 348: 1241–4.
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